|
1
|
Han D, Wang M, Ma N, Xu Y, Jiang Y and Gao
X: Long non-coding RNAs: Novel players in colorectal cancer. Cancer
Lett. 361:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li PL, Zhang X, Wang LL, Du LT, Yang YM,
Li J and Wang CX: MicroRNA-218 is a prognostic indicator in
colorectal cancer and enhances 5-fluorouracil-induced apoptosis by
targeting BIRC5. Carcinogenesis. 36:1484–1493. 2015.PubMed/NCBI
|
|
3
|
Tomida C, Aibara K, Yamagishi N, Yano C,
Nagano H, Abe T, Ohno A, Hirasaka K, Nikawa T and Teshima-Kondo S:
The malignant progression effects of regorafenib in human colon
cancer cells. J Med Invest. 62:195–198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Alberts SR, Horvath WL, Sternfeld WC,
Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S,
Sargent DJ, et al: Oxaliplatin, fluorouracil, and leucovorin for
patients with unresectable liver-only metastases from colorectal
cancer: A North Central Cancer Treatment Group phase II study. J
Clin Oncol. 23:9243–9249. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goldberg RM, Sargent DJ, Morton RF, Fuchs
CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC and Alberts
SR: A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan, and oxaliplatin combinations in patients with
previously untreated metastatic colorectal cancer. J Clin Oncol.
22:23–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamauchi K, Yang M, Hayashi K, Jiang P,
Yamamoto N, Tsuchiya H, Tomita K, Moossa AR, Bouvet M and Hoffman
RM: Induction of cancer metastasis by cyclophosphamide pretreatment
of host mice: An opposite effect of chemotherapy. Cancer Res.
68:516–520. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q,
Tang F, Chen ZQ, Liu XP and Xu ZD: Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to
multidrug resistance and invasive potential in breast cancer cells.
Clin Cancer Res. 15:2657–2665. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li-Weber M: Targeting apoptosis pathways
in cancer by Chinese medicine. Cancer Lett. 332:304–312. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang MJ and Huang J: Recent research
progress of anti-tumor mechnism matrine. Zhongguo Zhong Yao Za Zhi.
29:115–118. 2004.(In Chinese). PubMed/NCBI
|
|
10
|
Liang L and Huang J: Oxymatrine inhibits
epithelial-mesenchymal transition through regulation of NF-κB
signaling in colorectal cancer cells. Oncol Rep. 36:1333–1338.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fei ZW, Qiu MK, Qi XQ, Dai YX, Wang SQ,
Quan ZW, Liu YB and Ou JM: Oxymatrine suppresses proliferation and
induces apoptosis of hemangioma cells through inhibition of HIF-1a
signaling. Int J Immunopathol Pharmacol. 28:201–208. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen H, Zhang J, Luo J, Lai F, Wang Z,
Tong H, Lu D, Bu H, Zhang R and Lin S: Antiangiogenic effects of
oxymatrine on pancreatic cancer by inhibition of the NF-κB-mediated
VEGF signaling pathway. Oncol Rep. 30:589–595. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kapranov P, Cheng J, Dike S, Nix DA,
Duttagupta R, Willingham AT, Stadler PF, Hertel J, Hackermüller J,
Hofacker IL, et al: RNA maps reveal new RNA classes and a possible
function for pervasive transcription. Science. 316:1484–1488. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pang EJ, Yang R, Fu XB and Liu YF:
Overexpression of long non-coding RNA MALAT1 is correlated with
clinical progression and unfavorable prognosis in pancreatic
cancer. Tumour Biol. 36:2403–2407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren S, Wang F, Shen J, Sun Y, Xu W, Lu J,
Wei M, Xu C, Wu C, Zhang Z, et al: Long non-coding RNA metastasis
associated in lung adenocarcinoma transcript 1 derived miniRNA as a
novel plasma-based biomarker for diagnosing prostate cancer. Eur J
Cancer. 49:2949–2959. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ji P, Diederichs S, Wang W, Böing S,
Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, et
al: MALAT-1, a novel non-coding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F
and Liu Y: TGF-β-induced upregulation of malat1 promotes bladder
cancer metastasis by associating with suz12. Clin Cancer Res.
20:1531–1541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hirata H, Hinoda Y, Shahryari V, Deng G,
Nakajima K, Tabatabai ZL, Ishii N and Dahiya R: Long non-coding RNA
MALAT1 promotes aggressive renal cell carcinoma through Ezh2 and
interacts with miR-205. Cancer Res. 75:1322–1331. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi Y, Ooi HS, Wu J, Chen J, Zhang X, Tan
S, Yu Q, Li YY, Kang Y, Li H, et al: MALAT1 long ncRNA promotes
gastric cancer metastasis by suppressing PCDH10. Oncotarget.
7:12693–12703. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ji Q, Liu X, Fu X, Zhang L, Sui H, Zhou L,
Sun J, Cai J, Qin J, Ren J, et al: Resveratrol inhibits invasion
and metastasis of colorectal cancer cells via MALAT1 mediated
Wnt/β-catenin signal pathway. PLoS One. 8:e787002013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long non-coding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li P, Zhang X, Wang H, Wang L, Liu T, Du
L, Yang Y and Wang C: MALAT1 is associated with poor response to
oxaliplatin-based chemotherapy in colorectal cancer patients and
promotes chemoresistance through EZH2. Mol Cancer Ther. 16:739–751.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho SF, Chang YC, Chang CS, Lin SF, Liu
YC, Hsiao HH, Chang JG and Liu TC: MALAT1 long non-coding RNA is
overexpressed in multiple myeloma and may serve as a marker to
predict disease progression. BMC Cancer. 14:8092014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren S, Liu Y, Xu W, Sun Y, Lu J, Wang F,
Wei M, Shen J, Hou J, Gao X, et al: Long non-coding RNA MALAT-1 is
a new potential therapeutic target for castration resistant
prostate cancer. J Urol. 190:2278–2287. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gong W, Wang Z, Wan Y, Shi L and Zhou Y:
Downregulation of ABCG2 protein inhibits migration and invasion in
U251 glioma stem cells. Neuroreport. 25:625–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang B, Han Q and Zhu Y: Oxymatrine
inhibited cell proliferation by inducing apoptosis in human lung
cancer A549 cells. Biomed Mater Eng. 26 Suppl 1:S165–S172.
2015.PubMed/NCBI
|
|
28
|
Guo B, Zhang T, Su J, Wang K and Li X:
Oxymatrine targets EGFRp-Tyr845 and inhibits
EGFR-related signaling pathways to suppress the proliferation and
invasion of gastric cancer cells. Cancer Chemother Pharmacol.
75:353–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang
B and Zheng S: Oxymatrine induces human pancreatic cancer PANC-1
cells apoptosis via regulating expression of Bcl-2 and IAP
families, and releasing of cytochrome c. J Exp Clin Cancer Res.
30:662011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu
W, Qi X, Zhu X, Pei Y and Lin H: Oxymatrine diminishes the side
population and inhibits the expression of β-catenin in MCF-7 breast
cancer cells. Med Oncol. 28 Suppl 1:S99–S107. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hector S, Bolanowska-Higdon W, Zdanowicz
J, Hitt S and Pendyala L: In vitro studies on the mechanisms of
oxaliplatin resistance. Cancer Chemother Pharmacol. 48:398–406.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samimi G, Manorek G, Castel R, Breaux JK,
Cheng TC, Berry CC, Los G and Howell SB: cDNA microarray-based
identification of genes and pathways associated with oxaliplatin
resistance. Cancer Chemother Pharmacol. 55:1–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gutschner T, Hämmerle M and Diederichs S:
MALAT1 - a paradigm for long non-coding RNA function in cancer. J
Mol Med. 91:791–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen W, Xu XK, Li JL, Kong KK, Li H, Chen
C, He J, Wang F, Li P, Ge XS, et al: MALAT1 is a prognostic factor
in glioblastoma multiforme and induces chemoresistance to
temozolomide through suppressing miR-203 and promoting thymidylate
synthase expression. Oncotarget. 8:22783–22799. 2017.PubMed/NCBI
|
|
35
|
Yuan P, Cao W, Zang Q, Li G, Guo X and Fan
J: The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance
of hepatocellular carcinoma cells via modulating autophagy. Biochem
Biophys Res Commun. 478:1067–1073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao X, Zhao R, Chen Q, Zhao Y, Zhang B,
Zhang Y, Yu J, Han G, Cao W, Li J, et al: MALAT1 might be a
predictive marker of poor prognosis in patients who underwent
radical resection of middle thoracic esophageal squamous cell
carcinoma. Cancer Biomark. 15:717–723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu M, Sun W, Liu Y and Dong X: The role
of lncRNA MALAT1 in bone metastasis in patients with non-small cell
lung cancer. Oncol Rep. 36:1679–1685. 2016. View Article : Google Scholar : PubMed/NCBI
|
